Anti-CD20 Cell Therapies in Multiple Sclerosis—A Fixed Dosing Schedule for Ocrelizumab is Overkill

Jagannadha Avasarala
  • Drug Target Insights, January 2017, SAGE Publishing
  • DOI: 10.1177/1177392817737515
The author haven't finished explaining this publicationThe author haven't finished explaining this publication

The following have contributed to this page: Dr Jagannadha R Avasarala